{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:06:32Z","timestamp":1788627992671,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T00:00:00Z","timestamp":1319500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/pcan.2011.50","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T10:27:35Z","timestamp":1319538455000},"page":"93-99","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"A","family":"Spitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mattia-Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Chwalisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,25]]},"reference":[{"key":"BFpcan201150_CR1","unstructured":"American Cancer Society. Cancer Facts and Figures 2010. Available at \n                    http:\/\/www.cancer.org\/acs\/groups\/content\/@nho\/documents\/document\/acspc-024113.pdf\n                    \n                  . Accessed 12 August 2010."},{"issue":"5 Suppl","key":"BFpcan201150_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0090-4295(89)90108-8","volume":"33","author":"BR Cassileth","year":"1989","unstructured":"Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI et al. Patients\u2019 choice of treatment in Stage D prostate cancer. Urology 1989; 33 (5 Suppl): 57\u201362.","journal-title":"Urology"},{"key":"BFpcan201150_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531\u20131538.","journal-title":"BJU Int"},{"issue":"2 Suppl 1","key":"BFpcan201150_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0090-4295(02)02393-2","volume":"61","author":"DG McLeod","year":"2003","unstructured":"McLeod DG . Hormonal therapy: historical perspective to future directions. Urology 2003; 61 (2 Suppl 1): 3\u20137.","journal-title":"Urology"},{"key":"BFpcan201150_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1185\/030079906X96425","volume":"22","author":"R Berges","year":"2006","unstructured":"Berges R, Bello U . Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006; 22: 649\u2013655.","journal-title":"Curr Med Res Opin"},{"key":"BFpcan201150_CR6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0022-5347(05)64625-3","volume":"168","author":"FM Chu","year":"2002","unstructured":"Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC . A clinical study of 22.5 mg La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168: 1199\u20131203.","journal-title":"J Urol"},{"key":"BFpcan201150_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0090-4295(03)00330-3","volume":"62","author":"O Sartor","year":"2003","unstructured":"Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC . An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003; 62: 319\u2013323.","journal-title":"Urology"},{"key":"BFpcan201150_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0022-5347(05)00161-8","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS . A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006; 175: 533\u2013536.","journal-title":"J Urol"},{"issue":"Suppl 1","key":"BFpcan201150_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000056540","volume":"60","author":"UW Tunn","year":"1998","unstructured":"Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F . Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int 1998; 60 (Suppl 1): 9\u201316; discussion 16\u201317.","journal-title":"Urol Int"},{"key":"BFpcan201150_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","volume":"29","author":"EA Lundstrom","year":"2009","unstructured":"Lundstrom EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig 2009; 29: 757\u2013765.","journal-title":"Clin Drug Investig"},{"key":"BFpcan201150_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/pcan.2008.52","volume":"12","author":"UW Tunn","year":"2009","unstructured":"Tunn UW, Wiedey K . Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis 2009; 12: 83\u201387.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201150_CR12","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452\u20133458.","journal-title":"J Clin Oncol"},{"key":"BFpcan201150_CR13","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448\u20134456.","journal-title":"J Clin Oncol"},{"key":"BFpcan201150_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clon.2008.11.013","volume":"21","author":"JP Nobes","year":"2009","unstructured":"Nobes JP, Langley SE, Laing RW . Metabolic syndrome and prostate cancer: a review. Clin Oncol (R Coll Radiol) 2009; 21: 183\u2013191.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"BFpcan201150_CR15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188\u20132194.","journal-title":"Cancer"},{"key":"BFpcan201150_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<243::AID-PROS5>3.0.CO;2-C","volume":"29","author":"SO Asbell","year":"1996","unstructured":"Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M . Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29: 243\u2013248.","journal-title":"Prostate"},{"key":"BFpcan201150_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2","volume":"59","author":"R Fonseca","year":"1998","unstructured":"Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC . Anemia after orchiectomy. Am J Hematol 1998; 59: 230\u2013233.","journal-title":"Am J Hematol"},{"key":"BFpcan201150_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/BF03345745","volume":"32","author":"S Shahani","year":"2009","unstructured":"Shahani S, Braga-Basaria M, Maggio M, Basaria S . Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009; 32: 704\u2013716.","journal-title":"J Endocrinol Invest"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pcan201150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pcan201150","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pcan201150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:03:06Z","timestamp":1684472586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["BFpcan201150"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2011.50","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,25]]}}}